# Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Source: https://onco.cc/trials/nct07379047/  
OnCo record `nct07379047` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing NB003 in gastrointestinal stromal tumour, now recruiting.

## Summary

Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST) is a phase 2/3 interventional study registered as NCT07379047, led by Ningbo Newbay Technology Development, and recruiting on the registry. Official title: A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumours (GIST). Planned enrolment is 255 participants (estimated). The study started in 2026-05-11 and primary completion is expected in 2028-08-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: GISTAR-1
- Tags: ctgov-ingest
- Registry id: NCT07379047
- Phase: 2/3
- Setting: A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Sponsor: Ningbo Newbay Technology Development
- Enrolled: 255

## Sources

- ClinicalTrials.gov NCT07379047: https://clinicaltrials.gov/study/NCT07379047

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/)
- drugs: [NB003](https://onco.cc/drugs/nb003/)

---
JSON: https://onco.cc/api/v1/entities/nct07379047.json